A Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma

Development and Validation of a Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma: a Multicenter Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06656039

Enrollment

1200

Registered

2024-10-24

Start date

2024-01-01

Completion date

2024-10-10

Last updated

2024-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma, Clear Cell

Keywords

Renal Cell Carcinoma, Multimodal, Artificial Intelligence, Prognosis, Deep Learning, Multicentre Study

Brief summary

The main goal of this observational study is to construct a predictive recurrence model for renal clear cell carcinoma through an artificial intelligence multimodal algorithm, which will improve the prognosis and survival time of ccRCC patients by helping clinicians to formulate individualised follow-up and to screen for appropriate adjuvant therapy candidates.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with malignant renal tumours must have postoperative pathological confirmation of renal clear cell carcinoma with pathological TNM stage Ⅰ-Ⅲ; * Have available preoperative imaging * Have available post-operative pathological paraffin samples or HE-stained tissue sections * Must agree to and be able to comply with the study's visit schedule and other requirements as specified in the protocol, including follow-up visits by telephone

Exclusion criteria

* The patient's tumour type cannot be determined on the basis of histopathological sections * Simultaneous combination of primary tumours at other sites; * No regular follow-up imaging data * Cases in which other factors led the investigator to believe that enrolment was inappropriate * Cases that met all the inclusion criteria of the appeal and did not meet all the

Design outcomes

Primary

Measure	Time frame	Description
Disease free survival	Baseline, immediately after the surgery, Tumour recurrence or further follow-up, Three months after surgery, Six months after surgery, Every year after surgery, at least follow-up 2years, up to 10 years	Defined as from surgery to tumor recurrence or follow-up deadline

Countries

China

Outcome results